Leerink Partnrs Boosts Earnings Estimates for Exact Sciences

Exact Sciences Co. (NASDAQ:EXAS) – Stock analysts at Leerink Partnrs lifted their Q3 2025 earnings per share estimates for Exact Sciences in a research report issued on Monday, April 21st. Leerink Partnrs analyst P. Souda now anticipates that the medical research company will post earnings per share of $0.17 for the quarter, up from their previous estimate of $0.12. The consensus estimate for Exact Sciences’ current full-year earnings is ($0.58) per share.

EXAS has been the subject of a number of other reports. Benchmark reaffirmed a “buy” rating and set a $65.00 price target on shares of Exact Sciences in a research note on Monday, January 13th. Bank of America dropped their target price on Exact Sciences from $72.00 to $65.00 and set a “buy” rating for the company in a research report on Thursday, February 20th. William Blair reissued an “outperform” rating on shares of Exact Sciences in a research note on Thursday, February 20th. Scotiabank boosted their price objective on Exact Sciences from $70.00 to $73.00 and gave the company a “sector outperform” rating in a report on Monday, February 24th. Finally, Guggenheim reiterated a “buy” rating and issued a $60.00 target price on shares of Exact Sciences in a research note on Friday, April 11th. Two equities research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Exact Sciences currently has an average rating of “Moderate Buy” and a consensus price target of $69.25.

Exact Sciences Stock Up 2.4 %

NASDAQ EXAS opened at $44.15 on Tuesday. The company has a quick ratio of 1.93, a current ratio of 2.15 and a debt-to-equity ratio of 0.97. Exact Sciences has a 52 week low of $39.97 and a 52 week high of $72.83. The firm has a market capitalization of $8.20 billion, a price-to-earnings ratio of -7.93 and a beta of 1.14. The company has a fifty day moving average of $45.60 and a two-hundred day moving average of $54.62.

Exact Sciences (NASDAQ:EXAS) last posted its quarterly earnings data on Wednesday, February 19th. The medical research company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.23. The business had revenue of $713.42 million during the quarter, compared to analyst estimates of $701.45 million. Exact Sciences had a negative return on equity of 5.29% and a negative net margin of 37.29%.

Institutional Trading of Exact Sciences

Hedge funds have recently bought and sold shares of the stock. Envestnet Portfolio Solutions Inc. raised its position in shares of Exact Sciences by 309.0% in the 1st quarter. Envestnet Portfolio Solutions Inc. now owns 72,882 shares of the medical research company’s stock worth $3,155,000 after acquiring an additional 55,063 shares in the last quarter. Chicago Capital LLC grew its stake in Exact Sciences by 38.6% in the first quarter. Chicago Capital LLC now owns 13,968 shares of the medical research company’s stock valued at $605,000 after purchasing an additional 3,888 shares during the last quarter. QRG Capital Management Inc. raised its holdings in Exact Sciences by 2.7% in the first quarter. QRG Capital Management Inc. now owns 43,589 shares of the medical research company’s stock worth $1,887,000 after purchasing an additional 1,128 shares in the last quarter. Exchange Traded Concepts LLC lifted its position in shares of Exact Sciences by 32.3% during the first quarter. Exchange Traded Concepts LLC now owns 15,442 shares of the medical research company’s stock valued at $668,000 after buying an additional 3,773 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC boosted its holdings in shares of Exact Sciences by 1.4% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 39,690 shares of the medical research company’s stock valued at $1,718,000 after buying an additional 555 shares in the last quarter. Hedge funds and other institutional investors own 88.82% of the company’s stock.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.